Biotechnology investing isn't for the faint of heart. Long investment periods, the perils of the FDA approval process, and a high mortality rate are a few of the issues that confront biotechnology investors. Venture capital investing in biotechnology start-ups has fallen off over the past few years, partly due to poor returns, but also because the long investment period doesn't work well in the typical 10-12 year life span of a venture capital fund. Xconomy.com has a good article on the new trends in biotechnology investing that are emerging to address some of these issues, and it's worth a read. Here's the link: http://www.xconomy.com/national/2012/04/09/investing-in-biotech-isnt-just-for-the-investors-anymore/
About this Blog
This Blog is a collection of thoughts on a variety of topics of interest to me, including:
Find me on LinkedIn
Find me on Twitter
All original works on this site are
© 2011-2018 Allen J. Latta. All rights reserved. Neither this website nor any portion thereof may be reproduced or used in any manner whatsoever
without the express prior written permission of Allen J. Latta.